An Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn) and Sinemet in Parkinson's Disease Subjects With Motor Fluctuations.

Trial Profile

An Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn) and Sinemet in Parkinson's Disease Subjects With Motor Fluctuations.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2011

At a glance

  • Drugs XP 21279 (Primary) ; Carbidopa; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Mar 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 12 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Phase I results in 10 patients reported by Xenoport.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top